Drug intelligence / Profile preview

FFT-135

Development stage: Preclinical
Lead developer: F5 Therapeutics
Modality: Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

FFT-135 is a drug candidate developed by F5 Therapeutics, Inc. It is designed for the treatment of neoplasms (cancers) and leverages the company's technology platforms, which include degrader-antibody conjugates and degradable molecular glue. These technologies are typically involved in targeted protein degradation.

Targets

EEF1A1 (Elongation Factor 1 Alpha)GSPT1 (G1 to S phase transition 1)GSPT2 (Eukaryotic peptide chain release factor GTP-binding subunit ERF3B)

Beyond the preview

Go deeper on FFT-135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FFT-135.

Explore the full profile